FCC is the cornerstone investor in the Special Opportunities Fund (The Fund), run by investment fund manager RYSE Asset Management.
The Fund is investing in health and care technologies and innovations to transform the current health and social care system, including improving access to and quality of care. The Fund is a unique collaboration to raise venture capital for innovations that transform and enhance care. The Fund will engage institutional and qualified investors to provide a financial lifeline for early-stage companies whose innovations can solve the challenges facing the NHS and other health and care delivery systems, ultimately transforming outcomes and enhancing quality of life and well-being.
The first investment was in Braingaze, a revolutionary new tool that uses eye tracking to help diagnose ADHD in a matter of minutes. The tool enables drug-free cognitive disorders treatment and brings brain-related healthcare into the digital and AI-powered age.
The second investment was in Curio Digital Therapeutics, a US-based innovation company treating postpartum depression (PPD) and other underserved women’s mental health conditions. Curio’s lead product, MamaLift Plus, is a prescription-only digital therapeutic, underpinned by a Connected Care platform which assesses women’s risk of depression and integrates her treatment with existing healthcare providers.
Although the Fund is anchored by FCC, both RYSE and FCC remain fully independent in order to be able to bring the full value of their expertise and broader perspectives to cutting-edge impactful work.
The Special Opportunities Fund is managed on behalf of its investing limited partners by RYSE Asset Management. Future Care Capital has no input in decision-making, although it can make introductions for the fund managers to consider.
Future Care Capital no longer makes direct investments of it’s own. Neither does it directly fund the acceleration of innovation development or implementation on behalf of providers or commissioners. We do, however, make applications to third-party grant funding organisations to support our work and recover operating costs.